Latest News

Listen: Novartis and the no good, very bad week

Why did Novartis keep its scandal to itself? Who knew what and when? And is there such thing as too much Peloton time?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. We went all Novartis this week, explaining the shocking news that the Swiss pharma giant submitted falsified data to the FDA and then waited three months to inform regulators. We discuss what we know, what remains unanswered, the implications for Novartis’s corporate rebrand, and why this was awkward timing for Vas Narasimhan, the company’s ascendant CEO.

Read the rest…

Source link

Related posts

Religion may play role in HPV vaccination rate for female college students

Newsemia

Determinants of Reperfusion Injury in the Diabetic Heart

Newsemia

In bid to improve care, Trump administration to relax privacy rules for patients with history of addiction

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy